To evolve thyroid cancer care to its highest level of excellence by providing the most comprehensive and personalized treatment to patients over a lifetime.
We will accomplish this by maintaining a detailed record of all aspects of individual thyroid cancer patients' disease and treatment in a database accessible (by permission) to all care providers as well as patients.
We will vigilantly monitor individual records and analyze comprehensive data to identify risk factors and new treatment opportunities for all our members. We will alert patients to timely follow up assessments and relevant research findings.
Through this collaborative system, patients will receive the benefit of centralized medical data reporting related to their thyroid cancer treatment to enhance the efficiency and accuracy of communication between care providers through a HIPAA compliant system.
Established in 2010, the Thyroid Cancer Care Collaborative (TCCC) is a unique concept in patient care.
The TCCC is both a tool to record and monitor individual patient records and a rigorous and comprehensive approach to analyzing data and applying results to the unique and specific needs of each patient. This is accomplished through the observation and research of dedicated professionals.
Our professionals, under the leadership of Dr. Mark Urken, represent experts in the fields of otolaryngology, general surgery, endocrinology, medical oncology and nuclear medicine.
The Thyroid Cancer Care Collaborative is funded by the THANC Foundation. The THANC (Thyroid, Head and Neck Cancer) Foundation was established in 2003. An essential part of its mission is to support research to better understand the cause and progression of thyroid cancer and advance new therapeutic approaches to relieve suffering and enhance quality of life of patients.
The TCC Reports on Treatment Options for Medullary Thyroid Cancer
Dr. Jochen Lorch discusses the lack of treatment options available for medullary thyroid cancer patients, as well as possible future treatment trials. Read More
Active Surveillance May Be Appropriate in Select Thyroid Cancer Patients
Dr. Tuttle and his research team reported that an active surveillance management approach to low-risk thyroid cancer could safely be employed. The TCC aims to alert patients and physicians on relevant research findings to identify new care strategies Read More
The TCC’s Updates on Pre-Operative Assessment in Defining Thyroid Cancer Molecular Profile
Researchers have identified certain characteristics of BRAF-positive and RAS-positive thyroid cancers that may help with improving pre-operative risk assessment for suggesting a molecular profile for the disease. Read More
The TCC's Updates on Ignyta's New Clinical Trial
Ignyta is coordinating a new clinical trial for TRK mutations, which are often seen in head and neck cancer patients. The TCC works to alert patients and physicians on relevant studies to identify new treatment opportunities for all patients. Read More